Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperacillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | CCKBR | P32239 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | FPR1 | P21462 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperacillin SCHEMBL10956851 | 1.00 | LMNA (0.78) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL34180 | 1.00 | LMNA (0.78) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL9374347 | 1.00 | LMNA (0.78) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL717962 | 1.00 | LMNA (0.78) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL1665895 | 0.99 | LMNA (0.77) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL11045258 | 0.98 | LMNA (0.76) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL11045255 | 0.98 | LMNA (0.76) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL10692696 | 0.98 | LMNA (0.75) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL24437361 | 0.93 | MEN1 (0.77) | LMNAKMT2AMEN1CCKBRKDM4E | |
| Piperacillin SCHEMBL33894 | 0.93 | MEN1 (0.77) | LMNAKMT2AMEN1CCKBRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227999-B2 | Antimicrobial cationic peptides and formulations thereof | CARRUS CAPITAL CORPORATION (CA) | 2016-01-05 | — | — | US | claimed |
| US-20150072957-A1 | Tazobactam Arginine Compositions | CALIXA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | claimed |
| EP-3866826-B1 | ANTIMICROBIAL PEPTIDES AND METHODS OF USING THE SAME | RIPTIDE BIOSCIENCE INC (US) | 2025-12-10 | — | — | EP | disclosed |
| CN-118252830-A | Use of compounds in the preparation of a medicament for preventing, treating, alleviating or alleviating fibrotic diseases | 厦门大学 | 2024-06-28 | — | — | CN | disclosed |
| US-11266712-B2 | Antimicrobial peptides and methods of using the same | Riptide Bioscience, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| CN-113226349-A | Antimicrobial peptides and methods of use thereof | 激流生物科学有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210087565-A1 | ANTISENSE ANTIBIOTICS AND BACTERIAL SECRETION BASED DELIVERY SYSTEM TO ELIMINATE DRUG-RESISTANT BACTERIA | NATIONAL SCIENCE FOUNDATION | 2021-03-25 | — | — | US | disclosed |
| US-10913790-B2 | Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200385715-A1 | COMPOSITIONS AND METHODS FOR ALTERING BACTERIA FITNESS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-12-10 | — | — | US | disclosed |
| US-10842811-B2 | Inulin for preventing antibiotic resistant infection and pathogen colonization | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200230200-A1 | Antimicrobial Peptides and Methods of Using the Same | UNITED STATES GOVERNMENT | 2020-07-23 | — | — | US | disclosed |
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | BIOWEST THERAPEUTICS INC. (CA) | 2002-03-21 | — | — | US | disclosed |
| EP-1174439-A2 | Compositions and methods for treating infections using analogues of indolicidin | Micrologix Biotech, Inc. (CA) | 2002-01-23 | — | — | EP | disclosed |
| US-6180604-B1 | Compositions and methods for treating infections using analogues of indolicidin | MICROLOGIX BIOTECH INC. (CA) | 2001-01-30 | — | — | US | disclosed |
| EP-0966481-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | Micrologix Biotech, Inc. (CA) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999065506-A2 | CANCER THERAPY WITH INDOLICIDIN OR CATIONIC PEPTIDES AND THEIR POLYMER CONJUGATES | MICROLOGIX BIOTECH INC. (CA) | 1999-12-23 | — | — | WO | disclosed |
| EP-0925308-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | Micrologix Biotech, Inc. (CA) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998040401-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | MICROLOGIX BIOTECH INC. (CA) | 1998-09-17 | — | — | WO | disclosed |
| WO-1998007745-A9 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | — | 1998-04-23 | — | — | WO | disclosed |
| WO-1998007745-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH, INC. (CA) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072957-A1 | Tazobactam Arginine Compositions | PRMT6, PRMT9, PRMT3 | LMNA 3815/4885KMT2A 439/4885MEN1 3175/4885 |
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | VIP, PEPD, PTMS | LMNA 2666/4885KMT2A 4586/4885MEN1 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.